Associations between Bone, Fat Tissue and Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus

 

 Buy Article Permissions and Reprints

Abstract

Aims: To investigate the relationship between bone-derived osteocalcin (OC), osteoprotegerin (OPG), Receptor Activator of Nuclear Factor NF-ĸB ligand (RANKL), and fat tissue-derived leptin and adiponectin with a clinical outcome of type 1 diabetes mellitus (T1DM) in children and adolescents.

Methods: 78 patients (43 girls and 35 boys), aged 11.5±4.3 years with T1DM and 11 age- and BMI-matched controls were included into the study. Patients were divided into 3 groups according to HbA1c level, I – below 7% [53 mmol/mol], II – 7–9% [53–75 mmol/mol] and III – above 9% [75 mmol/mol]. Blood samples for biochemical measurements were drawn at 8.00 AM, when the patients were in a fasting state. HbA1c was measured by the standardized IFCC method. OC, OPG, RANKL, leptin and adiponectin were measured by ELISA. ANOVA, and multiple regression analysis were used for statistical analysis.

Results: Significant differences in leptin and osteocalcin levels between groups with different HbA1c values were observed (p=0.03, p=0.04). Multiple regression analysis adjusted for age showed that serum OC and leptin negatively correlated with HbA1c levels (r=−0.22, p=0.004 and r=−0.27, p=0.0001, respectively). In contrast, serum OPG correlated positively with HbA1c (r=0.26, p=0.02) as well as with adiponectin (r=0.26, p=0.02) and RANKL (r=0.27, p=0.02) levels. The correlation of OC with HbA1c was the strongest in group I – patients with good metabolic control of DM (r=−0.43, p=0.03). In that group, in multiple regression analysis adjusted for age and BMI leptin correlated positively with daily dose of insulin (r=0.52, r=0.009). In group II and III in multiple regression analysis adjusted for age and BMI OC correlated negatively with leptin (r=−0.37, p=0.01).

Conclusions: Our data suggest significant relationships between bone, fat tissue and glucose metabolism in pediatric patients with T1DM. The results can confirm that poor metabolic control is associated with reduced bone formation. On the other hand fat and bone tissue can influence glucose metabolism, potentiality in insulin-dependent manner. From these data leptin or OC may be potentially used as additional therapeutic agents for T1DM.

• References

• 1 Ducy P, Desbois C, Boyce B et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452
  CrossrefPubMedGoogle Scholar
• 2 Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
  CrossrefPubMedGoogle Scholar
• 3 Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 2008; 19: 161-166
  CrossrefPubMedGoogle Scholar
• 4 Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev 2009; 5: 365-372
  PubMedGoogle Scholar
• 5 Manolagas S. Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endo Rev 2000; 21: 115-137
  PubMedGoogle Scholar
• 6 Chen D, Zhao M, Mundy GR. Bone morphogenic proteins. Growth Factors 2004; 22: 233-241
  Google Scholar
• 7 Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Clin Endocrinol Metab 2005; 90: 6323-6331
  CrossrefPubMedGoogle Scholar
• 8 Wada T, Nakashima T, Hiroshi N et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25
  CrossrefPubMedGoogle Scholar
• 9 Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
  CrossrefPubMedGoogle Scholar
• 10 Cofavreux CB, Levine RL, Karsenty G. A paradigm between serum osteocalcin and markers of metabolic phenotype. Mol Cell Endocrinol 2009; 310: 21-29
  CrossrefPubMedGoogle Scholar
• 11 Ferron M, Wei J, Yoshizawa T et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010; 142: 296-308
  CrossrefPubMedGoogle Scholar
• 12 Ferron M, McKee MD, Levine RL et al. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 2012; 50: 568-575
  CrossrefPubMedGoogle Scholar
• 13 Oshima K, Nampei A, Matsuda M et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331: 520-526
  CrossrefPubMedGoogle Scholar
• 14 Luo XH, Guo LJ, Yuan LQ et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005; 309: 99-109
  CrossrefPubMedGoogle Scholar
• 15 Hinoi E, Gao N, Jung DY et al. The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 2008; 183: 1235-1242
  CrossrefPubMedGoogle Scholar
• 16 Ravipati S, Rajkumar B. Role of leptin in diabetes mellitus. Ind J Fund Appl Life Sci 2011; 1: 209-214
  PubMedGoogle Scholar
• 17 Kanazawa I, Yamaguchi T, Yamamoto M et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 45-49
  CrossrefPubMedGoogle Scholar
• 18 Saleem U, Mosley Jr TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30: 1474-1478
  CrossrefPubMedGoogle Scholar
• 19 Tamura T, Yoneda M, Yamane K et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 623-628
  CrossrefPubMedGoogle Scholar
• 20 Prats-Puig A, Mas-Parareda M, Riera-Perez E et al. Carboxylation of osteocalcin affects its association with metabolic parameters in healthy children. Diabetes Care 2010; 33: 661-663
  CrossrefPubMedGoogle Scholar
• 21 Reinehr T, Roth C. A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss. IJO 2010; 34: 852-858
  PubMedGoogle Scholar
• 22 Polish Diabetes Association . Clinical recommendations regarding the management of patients with diabetes mellitus 2013. Clinical Diabetology 2013; 2: A1-A70
  PubMedGoogle Scholar
• 23 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412
  CrossrefPubMedGoogle Scholar
• 24 Palczewska I, Niedźwiecka Z. Siatki centylowe do oceny rozwoju somatycznego dzieci i młodzieży. Warszawa: Instytut Matki i Dziecka; 1999
  Google Scholar
• 25 Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999; 48: 1487-1492
  CrossrefPubMedGoogle Scholar
• 26 Miyanaga F, Ogawa Y, Ebihara K et al. Leptin as an adjunct on insulin therapy in insulin-deficient diabetes. Diabetologia 2003; 46: 1329-1337
  CrossrefPubMedGoogle Scholar
• 27 Wang M, Chen L, Clark GO et al. Leptin therapy in insulin-deficient type I diabetes. PNAS 2010; 107: 4813-4819
  CrossrefPubMedGoogle Scholar
• 28 Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000; 37: 432-446
  CrossrefPubMedGoogle Scholar
• 29 Kaji H, Hisa I, Inoue Y et al. Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab 2009; 27: 76-82
  CrossrefPubMedGoogle Scholar
• 30 Yamauchi T, Yamaguchi T, Nawata K et al. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr 2010; 29: 761-765
  CrossrefPubMedGoogle Scholar